| __timestamp | BioMarin Pharmaceutical Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 5699000000 |
| Thursday, January 1, 2015 | 402271000 | 5001000000 |
| Friday, January 1, 2016 | 476593000 | 5002000000 |
| Sunday, January 1, 2017 | 554336000 | 4849000000 |
| Monday, January 1, 2018 | 604353000 | 4551000000 |
| Tuesday, January 1, 2019 | 680924000 | 4871000000 |
| Wednesday, January 1, 2020 | 737669000 | 7661000000 |
| Friday, January 1, 2021 | 759375000 | 7690000000 |
| Saturday, January 1, 2022 | 854009000 | 7814000000 |
| Sunday, January 1, 2023 | 937300000 | 7772000000 |
| Monday, January 1, 2024 | 1009025000 | 8414000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. Over the past decade, Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BioMarin's SG&A expenses surged by over 200%, reflecting its aggressive expansion and investment in innovation. In contrast, Bristol-Myers Squibb maintained a more stable trajectory, with a modest 36% increase, peaking in 2022. This divergence highlights the strategic choices each company makes in balancing growth and operational efficiency. As the industry faces increasing pressure to innovate while controlling costs, these insights offer a glimpse into the financial strategies shaping the future of pharmaceuticals.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Mesoblast Limited
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends